title: Influence of the xanthine derivate HWA 138 on endotoxin-related coagulation disturbances: effects in non-sensitized vs D-galactosamine sensitized rats.
abstract: We have evaluated the effects of the xanthine derivate HWA 138 in rat endotoxemia in order to 1) prevent coagulation disturbances and other endotoxin-induced physiological abnormalities and 2) to reduce mortality. We performed two studies using two different models (sensitized vs non-sensitized rats) with a similar mortality but different severity of coagulation disturbances: a) LPS (15 mg/kg) alone or with HWA 138 (80 mg/kg) as a treatment modality 30 min pre LPS, b) galactosamine (500 mg/kg) simultaneously with LPS (100 micrograms/kg) with or without HWA 138 (80 mg/kg) pretreatment. Experiments c) and d) employed D-galactosamine and/or LPS similar to experiments a) and b), while HWA 138 was applied simultaneously. We found significant 1) amelioration of life-threatening coagulation disturbances in non-sensitized rats, 2) prevention of liver dysfunction in sensitized rats, 3) reduction of TNF formation in both models, and 4) improvement of survival in all groups receiving HWA 138. Our data indicate protective effects of HWA 138 against clotting disturbances either directly via reduced LPS-induced formation of procoagulant activity or indirectly via reduced TNF formation.
authors.affiliation: Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Bahrami
authors.forename: H
authors.initials: H
authors.lastname: Redl
authors.forename: W A
authors.initials: WA
authors.lastname: Buurman
authors.forename: G
authors.initials: G
authors.lastname: Schlag
mesh_terms: D000818:Animals; D000990:Antithrombin III / Q000378:metabolism; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality; D001786:Blood Glucose / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005688:Galactosamine / Q000276:immunology*; D006403:Hematologic Tests; D007114:Immunization; D066298:In Vitro Techniques; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000633:toxicity*; D008297:Male; D010314:Partial Thromboplastin Time; D010431:Pentoxifylline / Q000031:analogs & derivatives* / Q000494:pharmacology; D010976:Platelet Count; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D001786:Blood Glucose; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; C062028:1-(5-hydroxy-5-methylhexyl)-3-methylxanthine; D005688:Galactosamine; D000990:Antithrombin III; D005340:Fibrinogen; D010431:Pentoxifylline